News Releases

Costs for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and

U.S. SEC declares registration statements effective Each ADS represents 10 ordinary shares The Company's ordinary shares continue to trade on Euronext Amsterdam No new shares issued in connection with the Nasdaq listing LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ -- Pharming Group N.V.

Pharming Group announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.

Pharming Group announces that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2

Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today announces that it has publicly filed a registration statement with the U.S.

Pharming Group today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair.

Pharming Group announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).

Pharming Group N.V. announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.

Pharming Group N.V. presents its (unaudited) financial report for the nine months and third quarter ended 30 September 2020. Highlights: Continued solid performance and strong recovery of sales in Q3 2020 Delivered 9.2% increase in revenues, 19.8% increase in operating profit and 6.4% increase in

Pharming Group N.V. announces it will hold an Extraordinary General Meeting (EGM) of Shareholders on Friday 11 December 2020 at 14:00 CET. Further to Pharming’s announcement on 20 May 2020, the EGM will address the appointment of two new Supervisory Directors, Ms. Barbara Yanni and Dr.